Pharmacokinetics of Anti‐VEGF Agent Aflibercept in Cancer Predicted by Data‐Driven, Molecular‐Detailed Model
Open Access
- 9 October 2015
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 4 (11) , 641-649
Abstract
Mathematical models can support the drug development process by predicting the pharmacokinetic (PK) properties of the drug and optimal dosing regimens. We have developed a pharmacokinetic model that includes a biochemical molecular interaction network linked to a whole-body compartment model. We applied the model to study the PK of the anti-vascular endothelial growth factor (VEGF) cancer therapeutic agent, aflibercept. Clinical data is used to infer model parameters using a Bayesian approach, enabling a quantitative estimation of the contributions of specific transport processes and molecular interactions of the drug that cannot be examined in other PK modeling, and insight into the mechanisms of aflibercept's antiangiogenic action. Additionally, we predict the plasma and tissue concentrations of unbound and VEGF-bound aflibercept. Thus, we present a computational framework that can serve as a valuable tool for drug development efforts.Keywords
Funding Information
- National Institutes of Health (R01 CA138264, F32 CA154213)
- European Research Council (341117)
This publication has 24 references indexed in Scilit:
- Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunitiesFrontiers in Pharmacology, 2015
- Computational systems biology approaches to anti-angiogenic cancer therapeuticsDrug Discovery Today, 2015
- Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokineticsJournal of Pharmacokinetics and Pharmacodynamics, 2013
- Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2013
- Multiscale Mechanistic Modeling in Pharmaceutical Research and Development2011
- Physiologically-Based Pharmacokinetics in Drug Development and Regulatory ScienceAnnual Review of Pharmacology and Toxicology, 2011
- The Pharmacokinetic/Pharmacodynamic Pipeline: Translating Anticancer Drug Pharmacology to the ClinicThe AAPS Journal, 2011
- Pharmacokinetic/ Pharmacodynamic‐Driven Drug DevelopmentMount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 2010
- Development of Translational Pharmacokinetic–Pharmacodynamic ModelsClinical Pharmacology & Therapeutics, 2008
- VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockadeProceedings of the National Academy of Sciences, 2007